Literature DB >> 1280393

Determination of insulin-like growth factor-2 in feto-maternal circulation during human pregnancy.

T Kubota1, S Kamada, M Taguchi, T Aso.   

Abstract

In order to clarify the roles of insulin-like growth factors (IGFs) on the human maternal-fetal environment, IGF-2 and IGF-1 levels were investigated in human plasma and amniotic fluid during pregnancy. Initially, new radio-immunoassay (RIA) systems for human IGF-2 could be developed. The sensitivity of this assay was 17.5 pg/tube and the cross-reactivity with IGF-1 was 0.64%. The pattern of change of maternal plasma IGF-2 in early pregnancy differed from that of IGF-1, but both IGF levels increased progressively in the second half of gestation, and decreased to non-pregnancy levels in the puerperium. Maternal levels of IGF-2 were approximately seven times greater than those of IGF-1. The ratio of IGF-2 to IGF-1 was 3.2 in amniotic fluid. The IGF concentrations in amniotic fluid obtained in the second trimester were significantly greater than those of term specimens, and closely related to those of prolactin (PRL) in amniotic fluid. The highest IGF-2 to IGF-1 ratio (15.9) was found in umbilical vein plasma. On Sephadex G-150 gel-chromatography of maternal and fetal plasma at term, two apparent peaks of unsaturated IGF-2 binding protein (BP) could be detected in both 150 and 40 kilo dalton (kD) regions. One main peak of unsaturated IGF-2 BP could be determined in the 40 kD region in the amniotic fluid at term. High concentration of IGF-2 could be detected in feto-maternal circulation during human pregnancy.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1280393     DOI: 10.1530/acta.0.1270359

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  7 in total

Review 1.  Osteoporosis in pregnancy.

Authors:  W Khovidhunkit; S Epstein
Journal:  Osteoporos Int       Date:  1996       Impact factor: 4.507

Review 2.  Big babies and infant leukemia: a role for insulin-like growth factor-1?

Authors:  J A Ross; J P Perentesis; L L Robison; S M Davies
Journal:  Cancer Causes Control       Date:  1996-09       Impact factor: 2.506

3.  Timing of maternal supplementation of dried distillers grains during late gestation influences postnatal growth, immunocompetence, and carcass characteristics of Bos indicus-influenced beef calves.

Authors:  Elizabeth A Palmer; Marcelo Vedovatto; Rhaiza A Oliveira; Juliana Ranches; Joao M B Vendramini; Matthew H Poore; Thiago Martins; Mario Binelli; John D Arthington; Philipe Moriel
Journal:  J Anim Sci       Date:  2022-02-01       Impact factor: 3.159

4.  Chinese Herbal Medicine Fuzheng Kang-Ai Decoction Inhibited Lung Cancer Cell Growth through AMPKα-Mediated Induction and Interplay of IGFBP1 and FOXO3a.

Authors:  Fang Zheng; Jingjing Wu; Xiong Li; Qing Tang; LiJun Yang; Xiaobing Yang; WanYin Wu; Swei Sunny Hann
Journal:  Evid Based Complement Alternat Med       Date:  2016-02-04       Impact factor: 2.629

5.  Frequency of maternal supplementation of energy and protein during late gestation modulates preweaning growth of their beef offspring.

Authors:  Vinicius Izquierdo; Marcelo Vedovatto; Elizabeth A Palmer; Rhaiza A Oliveira; Hiran M Silva; João M B Vendramini; Philipe Moriel
Journal:  Transl Anim Sci       Date:  2022-08-18

6.  Monensin supplementation during late gestation of beef cows alters maternal plasma concentrations of insulin-like growth factors 1 and 2 and enhances offspring preweaning growth.

Authors:  Marcelo Vedovatto; Vinicius Izquierdo; Elizabeth Palmer; Rhaiza A Oliveira; Hiran M Silva; João M B Vendramini; Philipe Moriel
Journal:  Transl Anim Sci       Date:  2022-08-03

7.  The Gestational Effects of Maternal Appetite Axis Molecules on Fetal Growth, Metabolism and Long-Term Metabolic Health: A Systematic Review.

Authors:  Angelos Dimas; Anastasia Politi; George Papaioannou; Thomas M Barber; Martin O Weickert; Dimitris K Grammatopoulos; Sudhesh Kumar; Sophia Kalantaridou; Georgios Valsamakis
Journal:  Int J Mol Sci       Date:  2022-01-09       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.